Navigation Links
Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma
Date:9/23/2011

eavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2010 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc., its jointly owned subsidiary.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc.  


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015  NeuroSigma ® , Inc. (NeuroSigma), a ... results of an animal study of its Thin Film Nitinol ... by Mayo Clinic researchers at the 53 rd Annual ... Chicago, Illinois . A copy of the study abstract ... The study at Mayo Clinic was primarily funded through ...
(Date:5/4/2015)... 2015 Dynatronics Corporation (the "Company") (NASDAQ: ... rehabilitation and physical therapy products, announced today that ... approximately $4,000,000 in a private placement financing led ... affiliates (together with its affiliates, "Prettybrook"), a strategic ... The financing will provide Dynatronics with additional capital ...
(Date:5/4/2015)... 2015   Mallinckrodt plc (NYSE: MNK ), ... 13, 2015, at the Bank of America Merrill Lynch 2015 ... Las Vegas, Nev. ... Officer, and Cole Lannum , Senior Vice President of ... in a session scheduled to begin at 3 p.m. Eastern ...
Breaking Medicine Technology:NeuroSigma's Thin Film Nitinol Flow Diverting Stent Results Presented at the American Society of Neuroradiology Meeting 2NeuroSigma's Thin Film Nitinol Flow Diverting Stent Results Presented at the American Society of Neuroradiology Meeting 3NeuroSigma's Thin Film Nitinol Flow Diverting Stent Results Presented at the American Society of Neuroradiology Meeting 4Dynatronics Announces $4,000,000 Private Placement Led By Prettybrook Partners 2Dynatronics Announces $4,000,000 Private Placement Led By Prettybrook Partners 3Dynatronics Announces $4,000,000 Private Placement Led By Prettybrook Partners 4Mallinckrodt To Present At Bank Of America Merrill Lynch 2015 Health Care Conference 2
... 04, 2007 /PRNewswire/ -- GlaxoSmithKline today,announced results ... in,advanced or metastatic renal cell carcinoma (RCC), ... trials were presented at the,43rd Annual Meeting ... in Chicago. The results observed in these ...
... Calif., June 04, 2007 /PRNewswire/ -- (SEND2PRESS,NEWSWIRE) -- ... historic landmark in medical oncology and a,definitive benchmark ... first clinical report of its kind, Le Morte ... the International Journal of,Oncology, Vol.30, pp. 1297-1307 -- ...
Cached Medicine Technology:GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 2GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 3GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 4GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 5GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 6GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 7News from the Battlefield of Metastatic Cancer: Epeius,Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G),from the Stone of Chemistry and Physics 2News from the Battlefield of Metastatic Cancer: Epeius,Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G),from the Stone of Chemistry and Physics 3
(Date:5/4/2015)... (PRWEB) May 04, 2015 Dr. Benjamin ... Georgia proudly offers the latest non-surgical double-chin eliminator. ... facial plastic surgeon in Atlanta to offer Kybella ... to be injected specifically under the chin, promising to ... , Before Kybella, patients who sought immediate solutions for ...
(Date:5/4/2015)... Morganville, NJ (PRWEB) May 04, 2015 ... that he has been chosen to receive the America’s ... Board. Dr. Champagne’s selection as a top dentist ... his commitment to continuing education and his compassion for ... Board selects professionals who exemplify excellence in their field. ...
(Date:5/4/2015)... For partners who’d like to become parents, ... Astroglide TTC™ (Trying to Conceive) . Unlike traditional lubricants ... Astroglide TTC™ is specially formulated to provide a better ... for Disease Control, an average of one in ... a pregnancy, and over 7.4 million women ...
(Date:5/4/2015)... The Accreditation for Cardiovascular ... congenital heart disease (CHD) standards for Pediatric ... Driven by the latest available clinical evidence, ... of interventional procedures in pediatric patients and ... ACE CHD Standards for PCCL Accreditation, like ...
(Date:5/4/2015)... May 04, 2015 Sara Soulati, CEO ... practice management firm in Los Angeles associated with the ... patent-pending status of The Sara Soulati Health For Life ... 2010, is a lifestyle modification and disease prevention program. ... to the U. S. Patents and Trademarks Office and ...
Breaking Medicine News(10 mins):Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Accreditation for Cardiovascular Excellence (ACE) Publishes New Standards for Pediatric and Adult Congenital Cardiac Catheterization Laboratories 2Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2
... are a valuable tool for controlling infectious diseases ... Routine immunizations and supplemental immunization activities, such as ... to entire populations. Current measurements used to determine ... flawed and inconsistent. According to a new study ...
... announces a partnership with the U.S. Food and Drug ... Center of Excellence in Regulatory Science and Innovation (CERSI). ... an initial $1 million grant, which is potentially part ... and manufacturing. Experts in science, medicine ...
... more rapid innovation in science and technology, Peter Thiel ... Breakout Labs. Speaking at Stanford to an event ... Thiel announced that Breakout Labs will use a revolving ... research is funded by helping independent scientists and early-stage ...
... building blocks of proteins, are essential to support the ... An insufficient supply of amino acids in the mother,s ... developmental abnormalities and complications of pregnancy that result in ... cutting-edge article in the peer-reviewed journal Cellular Reprogramming ...
... , WEDNESDAY, Oct. 26 (HealthDay News) -- People ... attempt to boost their social status, a new study suggests. ... portions with higher social standing. For example, study participants believed ... social status than those who chose a medium or small ...
... New research has the potential to revolutionize the treatment ... a million Canadians which is expected to strike even more ... AF is the most common type of heart arrhythmia ... greater risk for stroke. Now, there is a new drug ...
Cached Medicine News:Health News:Researchers develop method to better estimate vaccine coverage 2Health News:FDA awards Georgetown University a Center of Excellence in Regulatory Science & Innovation 2Health News:FDA awards Georgetown University a Center of Excellence in Regulatory Science & Innovation 3Health News:Peter Thiel announces Breakout Labs to energize innovation 2Health News:Inadequate supply of protein building blocks may explain pregnancy failures in bovine cloning experiments 2Health News:Larger Food Portions May Be Seen as Status Symbols 2Health News:ARISTOTLE trial finds new drug may revolutionize the treatment of atrial fibrillation 2Health News:ARISTOTLE trial finds new drug may revolutionize the treatment of atrial fibrillation 3
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
This is a single-action instrument that features a spring handle....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
Medicine Products: